{
 "papers": [
  {
   "slug": "cdk2",
   "title": "Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2",
   "authors_short": "Hummel et al.",
   "year": 2024,
   "target": "CDK2",
   "one_line": "A screening hit that was really a JAK2 inhibitor, turned into a CDK2 inhibitor selective over five other CDKs.",
   "bundle_version": "1.0.0"
  },
  {
   "slug": "fgfr",
   "title": "Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3",
   "authors_short": "Shvartsbart et al.",
   "year": 2022,
   "target": "FGFR3",
   "one_line": "An inhibitor that still works on the gatekeeper mutants that defeat the approved pan-FGFR drugs, while sparing FGFR1.",
   "bundle_version": "1.0.0"
  },
  {
   "slug": "kras",
   "title": "Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor",
   "authors_short": "Ye et al.",
   "year": 2025,
   "target": "KRAS G12D",
   "one_line": "Aspartate is not cysteine, so the covalent trick that beat KRAS G12C does not work here. This one binds without a warhead.",
   "bundle_version": "1.0.0"
  },
  {
   "slug": "jak1",
   "title": "Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases",
   "authors_short": "Zhuo et al.",
   "year": 2026,
   "target": "JAK1",
   "one_line": "Sparing JAK2 is the whole point: inhibit it and you take the patient's blood counts with you.",
   "bundle_version": "1.0.0"
  }
 ]
}